Skip to content
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • Jylamvo
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact

Company Updates

Tepylute

FDA Approval and U.S. Launch of Tepylute® 15 MG AND 100 MG

April 29th 2025April 29th 2025

Read More

Shorla Oncology attending Asembia 2025

Shorla Oncology is attending AXS25 SUMMIT April 27 – May 1, 2025

April 23rd 2025

Read More

Shorla Oncology

Shorla Oncology is attending the PCMA Annual Meeting March 10-11 2025

March 10th 2025

Read More

Milan

Audrene Rice, Our R&D Pipeline and Portfolio Manager, is attending  Bio-Europe from March 17-19 in Milan, Italy

March 10th 2025

Read More

BW

Shorla Oncology Announces Expansion of U.S. Commercial Footprint with Launch of Dedicated Sales Force and Market Access Teams

March 4th 2025March 4th 2025

Read More

GPTW

We are delighted to be recognised as a Best Workplace by Great Place to Work

February 27th 2025February 27th 2025

Read More

Bussiness Awards 2024

Sharon and Orlaith were recently awarded the Irish Times Future Leaders award

February 24th 2025

Read More

San Bridge

We are attending the JP Morgan Healthcare Conference 2025 in San Francisco January 13-16. We look forward to meeting you there.

February 20th 2025December 9th 2024

Read More

EY

Shorla Oncology co-founders win EY Entrepreneurs of the Year award

December 2nd 2024

Read More

Older posts
Page1 Page2 … Page12
Logo

IRELAND HQ:
Questum Acceleration Center,
Ballingarrane Science & Technology Park,
Clonmel, Co. Tipperary,
E91 V329, Ireland

Shorla Pharma Ltd trading as Shorla Oncology®

All trademarks are the property of their respective owners.

US OFFICE:
245 Main St.,
2nd floor,
Cambridge,
MA 02142, USA

SITEMAP
PRIVACY POLICY
Company number: 618033
©SHORLA ONCOLOGY® 2025

© 2025 Shorla Oncology: A Leader in Innovative Oncology Solutions • Built with GeneratePress
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • Jylamvo
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact

Now approved for use in Pediatrics

  • Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA).
  • Treatment of pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.

Please click here for the full Prescribing information, including Boxed Warning regarding embryo-fetal toxicity, hypersensitivity reactions, and severe adverse reactions.